BSE Live
Apr 06, 16:01Prev. Close
969.75
Open Price
981.05
Bid Price (Qty.)
970.00 (1)
Offer Price (Qty.)
986.20 (49)
NSE Live
Apr 06, 15:57Prev. Close
971.15
Open Price
971.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
981.05 (224)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 89.57 | 89.55 | 89.50 | 89.42 | 89.35 | |
| Total Share Capital | 89.57 | 89.55 | 89.50 | 89.42 | 89.35 | |
| Reserves and Surplus | 3,079.88 | 3,159.68 | 3,072.37 | 3,143.10 | 3,046.06 | |
| Total Reserves and Surplus | 3,079.88 | 3,159.68 | 3,072.37 | 3,143.10 | 3,046.06 | |
| Total Shareholders Funds | 3,175.17 | 3,256.80 | 3,161.87 | 3,232.53 | 3,135.41 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.15 | 2.45 | 769.45 | 880.70 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 33.62 | |
| Other Long Term Liabilities | 42.55 | 3.98 | 3.33 | 22.52 | 14.99 | |
| Long Term Provisions | 19.75 | 12.88 | 13.32 | 22.58 | 10.14 | |
| Total Non-Current Liabilities | 62.30 | 17.01 | 19.10 | 814.56 | 939.45 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 852.46 | 808.80 | 601.59 | 647.44 | 544.41 | |
| Trade Payables | 474.11 | 509.40 | 390.72 | 470.56 | 497.17 | |
| Other Current Liabilities | 92.44 | 49.49 | 84.90 | 290.28 | 195.69 | |
| Short Term Provisions | 18.78 | 21.31 | 26.84 | 25.87 | 51.87 | |
| Total Current Liabilities | 1,437.79 | 1,388.99 | 1,104.05 | 1,434.16 | 1,289.13 | |
| Total Capital And Liabilities | 4,675.25 | 4,662.80 | 4,285.16 | 5,481.24 | 5,363.99 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 493.52 | 444.59 | 432.51 | 837.87 | 781.73 | |
| Intangible Assets | 49.79 | 52.14 | 65.45 | 285.90 | 277.11 | |
| Capital Work-In-Progress | 86.03 | 72.56 | 86.89 | 99.63 | 126.42 | |
| Other Assets | 72.36 | 76.88 | 66.00 | 70.07 | 0.00 | |
| Fixed Assets | 724.48 | 696.07 | 707.81 | 1,351.58 | 1,238.92 | |
| Non-Current Investments | 2,170.57 | 1,994.59 | 1,465.19 | 1,240.70 | 1,233.92 | |
| Deferred Tax Assets [Net] | 81.04 | 80.12 | 53.51 | 19.34 | 0.00 | |
| Long Term Loans And Advances | 96.07 | 91.61 | 37.49 | 54.81 | 230.26 | |
| Other Non-Current Assets | 146.30 | 136.82 | 521.61 | 235.65 | 1.90 | |
| Total Non-Current Assets | 3,218.45 | 2,999.21 | 2,785.62 | 2,902.08 | 2,704.99 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 154.29 | 311.48 | 1,279.54 | 1,132.95 | |
| Inventories | 444.86 | 473.34 | 269.63 | 409.53 | 379.23 | |
| Trade Receivables | 661.46 | 582.56 | 449.37 | 540.69 | 702.30 | |
| Cash And Cash Equivalents | 108.43 | 180.81 | 79.79 | 94.92 | 94.34 | |
| Short Term Loans And Advances | 77.16 | 27.60 | 26.23 | 8.65 | 326.16 | |
| OtherCurrentAssets | 164.89 | 244.99 | 363.05 | 245.84 | 24.03 | |
| Total Current Assets | 1,456.80 | 1,663.59 | 1,499.54 | 2,579.16 | 2,659.01 | |
| Total Assets | 4,675.25 | 4,662.80 | 4,285.16 | 5,481.24 | 5,363.99 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 3,498.11 | 5,766.31 | 4,437.15 | 5,478.48 | 5,370.32 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 406.52 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 11.98 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 11.98 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 37.96 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 31.05 | 39.50 | 71.02 | 0.00 | 72.75 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | 0.04 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | 1,519.23 | |
| Other Earnings | 1,602.02 | 1,462.98 | 1,569.71 | -- | 141.95 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | 0.11 | 1,240.70 | 1,233.92 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | 154.29 | 311.48 | 1,279.54 | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | 1,132.95 |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
07.04.2026
07.04.2026
06.04.2026
06.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth